Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2016

View Archived Issues

Apricus expands Vitaros agreement with Ferring, terminates agreement with Sandoz

Prokarium receives funding to develop three new vaccines

Cerecor announces research grant for the development of CERC-501

SRI International patents MAP4K4 inhibitors

Scripps Research Institute discloses agents to treat cancer

PTC provides E.U. and U.S. update on Translarna program

Interim data from REMARC study of Revlimid do not support regulatory filing

Parion Sciences begins phase II study of P-321

Genentech and Constellation Pharmaceuticals develop KAT2B inhibitors

Genentech and Constellation Pharmaceuticals jointly patent KDM2B inhibitors

NantHealth and University of Utah partner on Heritage 1K project

Kite Pharma licenses technology from UCLA

First-in-human data on BACE1 inhibitor LY-3202626

NY-ESO SPEAR T-cell therapy receives orphan drug designation in the E.U.

First patient dosed in phase III study of roxadustat in Japan

Tokai to discontinue ARMOR3-SV study of galeterone based on DMC recommendation

Embera Neurotherapeutics receives grant to continue development of drug for cocaine addition

Amgen and Novartis report first-in-human data on AMG-520

Preclinical and early clinical evaluation of MK-8719

Enigma Biomedical, Biogen and Merck & Co. establish research collaboration

Results from phase Ib trial evaluating second-generation NGF-ECB implants in patients with AD

Hisamitsu reports phase II results for HP-3150 analgesic transdermal patch

Trek Therapeutics gains rights to two HCV drugs from Vertex

NIAID gives grant to Forge Therapeutics to develop drugs for multidrug-resistant bacteria

Viking Therapeutics reports results of study in mice with VK-0214

Merck & Co. returns all rights to SLIT-tablets to ALK-Abello

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...